Dyssomnias
A broad category of sleep disorders characterized by either hypersomnolence or insomnia. The three major subcategories include intrinsic (i.e., arising from within the body) (SLEEP DISORDERS, INTRINSIC), extrinsic (secondary to environmental conditions or various pathologic conditions), and disturbances of circadian rhythm. (From Thorpy, Sleep Disorders Medicine, 1994, p187)
Subtype terms (3)
More specific conditions that are subtypes of Dyssomnias in the MeSH hierarchy.
- Sleep Deprivation
34 drugs (24 approved, 10 experimental)
- Sleep Disorders, Circadian Rhythm
20 drugs (13 approved, 7 experimental)
- Sleep Disorders, Intrinsic
113 drugs (76 approved, 37 experimental)
Drugs by status
Phase 3 trials (3)
Phase 2 trials (1)
Phase 1 trials (1)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (38)
- Takeda
- Forest Laboratories
- Gilead Sciences
- AstraZeneca
- Merck
- Kuhnil Pharmaceutical Co., Ltd.
- Teva
- Boehringer Ingelheim
- TTY Biopharm
- Region Syddanmark
- University of Pittsburgh
- Chang Gung University
- Cleveland Sleep Research Center
- Harvard University
- Inje University
- Johns Hopkins University
- Mental Health Services in the Capital Region, Denmark
- Midtown Medical Center, Tampa, FL
- University of Southern Denmark
- Yonsei University
- University of California, San Diego
- University of Ulsan
- CJ HealthCare Corp.
- Chungnam National University
- Competence Centre for Transcultural Psychiatry
- SouthWest Cleveland Sleep Center
- Soonchunhyang University
- Technical University of Dresden
- Department of Veteran Affairs
- University of Liege
- +8 more
Organization Involved with Phase 3 Indications (20)
- XenoPort, Inc.
- GlaxoSmithKline
- Neurim Pharmaceuticals Ltd.
- National Institute on Aging (NIA)
- Herlev Hospital
- University of London
- Loma Linda University
- Meander Medical Center
- Oregon Health and Science University
- University of Cincinnati
- University of Copenhagen
- Free University of Amsterdam
- Koege and Roskilde Hospital
- Psychiatric Research Unit, Region Zealand
- National Taiwan University
- Pennsylvania State University
- Dutch Kidney Foundation
- Pharma Nord
- Lundbeck
- Avadel Pharmaceuticals
Organization Involved with Phase 2 Indications (11)
- British Columbia Cancer Agency
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- Northern California Institute of Research and Education
- Rhode Island Hospital
- University of Michigan
- Department of Defense
- University of Texas at Houston
- Damon Runyon Cancer Research Foundation
- China Medical University
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (12)
- Jazz Pharmaceuticals
- National Institutes of Health (NIH)
- National Institute of Nursing Research (NINR)
- United States Army
- University of Arizona
- Baylor University
- University of Washington
- Stanford University
- Thomas Jefferson University
- University of Nebraska
- University of North Carolina at Chapel Hill
- Huntington's Disease Society of America